CHMA1004 dihydrochloride

Synonyms: Methyl piperazine-2-carboxylate dihydrochloride; METTL3 activator-1
CHMA1004(Methyl piperazine-2-carboxylate;METTL3 activator-1)二盐酸盐是一种 METTL3/METTL14/WTAP 甲基转移酶复合物激活剂,通过增强 RNA 的 m6A 甲基化修饰而表现出神经保护和抗焦虑潜力,并在感染背景下促进 HIV 复制,因此可用于焦虑症和 HIV-1 感染的相关研究。
产品编号: MS-X59995 纯度: 99.38% CAS No.: 122323-88-0 分子式: C6H14Cl2N2O2 分子量: 217.09
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
3-5 天
500mg
询价
3-5 天
1g
询价
询价
5g
询价
询价

产品描述

CHMA1004(Methyl piperazine-2-carboxylate;METTL3 activator-1)二盐酸盐是一种 METTL3/METTL14/WTAP 甲基转移酶复合物激活剂,通过增强 RNA 的 m6A 甲基化修饰而表现出神经保护和抗焦虑潜力,并在感染背景下促进 HIV 复制,因此可用于焦虑症和 HIV-1 感染的相关研究。

生物实验数据

生物活性 CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is an activator of the METTL3/METTL14/WTAP methyltransferase complex that exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation of RNA and promotes HIV replication in the context of infection, making it useful for research on anxiety disorders and HIV-1 infection.
体外研究
(In Vitro)

CHMA1004 dihydrochloride 可保护干细胞来源的人多巴胺神经元免受 6-OHDA 诱导的细胞死亡。
CHMA1004 (Compound 4) dihydrochloride (0.001-10 μM; 48 h) 可诱导 ACH-2 细胞中 HIV-1 p24 的释放呈浓度依赖性增加。
CHMA1004 (10 μM; 48 h) dihydrochloride 可促进 ACH-2 细胞产生具有感染性的 HIV-1 病毒颗粒,这一点可通过受感染的 TZM-bl 细胞中增强的荧光素酶活性得到验证。
CHMA1004 (10 μM; 48 h) dihydrochloride 可使 ACH-2 细胞 mRNA 中的 m6A 甲基化水平提升至原来的两倍以上,使 HIV-1 病毒 RNA 中的 m6A 甲基化水平提升约 18%。
CHMA1004 (1 nM-10 μM) dihydrochloride 可轻微提高 HEK-293 细胞 mRNA 中的 m6A 甲基化水平。

ELISA Assay

Cell Line: ACH-2 cells (harboring HIV-1 provirus)
Concentration: 0.001 μM, 0.01 μM, 0.1 μM, 1 μM, 10 μM
Incubation Time: 48 h
Result: Caused a concentration-dependent increase in HIV-1 p24 release (measured as optical density at 450 nm).
Showed statistically significant increases at 0.1 μM, 1 μM, and 10 μM compared to control.
体内研究
(In Vivo)

CHMA1004 (1-5 mg/kg;腹腔注射;每日给药,持续 17-18 天或单次剂量) dihydrochloride 可在雄性和雌性 Wistar 大鼠中引发类抗焦虑和运动激活效应,改变脑内单胺水平以及与神经精神通路相关的纹状体基因表达,且无强烈的精神兴奋特性。

Animal Model: Wistar rats (male and female; 3 months old at study start; male body weight 499 g, female body weight 290 g)
Dosage: 1 mg/kg (subchronic; acute microdialysis); 5 mg/kg (subchronic; acute microdialysis)
Administration: i.p.; daily; 17-18 days (subchronic); i.p.; single dose (acute microdialysis)
Result: Increased time spent moving, line crossings, and rearings in female rats in acute open field test.
Showed a similar non-significant tendency in males at 5 mg/kg in acute open field test.
Reduced faecal boli counts in male rats at 5 mg/kg in acute open field test.
Increased head-dips in female rats during the first repeated elevated zero-maze test at 1 mg/kg and 5 mg/kg.
Increased open quadrant entries in male rats during the second repeated elevated zero-maze test at 5 mg/kg.
Reduced stretched-attend postures in male rats during the first repeated elevated zero-maze test at 5 mg/kg.
Increased swimming time and reduced struggling time in female rats on both test days of repeated forced swimming test at 1 mg/kg and 5 mg/kg.
Tended to increase locomotion in male rats during amphetamine challenge at subchronic 5 mg/kg.
Reduced the baseline sex difference in 50-kHz USVs by increasing vocalisations in males and reducing them in females during amphetamine challenge at subchronic 5 mg/kg.
Had no significant effect on extracellular striatal dopamine levels in acute microdialysis at 1 mg/kg and 5 mg/kg.
Increased normetanephrine (NMN) levels in males and females in striatum at subchronic 5 mg/kg.
Increased the DOPAC/DA ratio in males in striatum at subchronic 5 mg/kg.
Decreased the DOPAC/DA ratio in females in striatum at subchronic 1 mg/kg.
Increased NMN levels in males in frontal cortex at subchronic 1 mg/kg and 5 mg/kg.
Increased noradrenaline (NA) levels in males in frontal cortex at subchronic 5 mg/kg.
Increased homovanillic acid (HVA) levels in males in locus coeruleus at subchronic 1 mg/kg.
Decreased HVA levels in females in locus coeruleus at subchronic 1 mg/kg and 5 mg/kg.
Increased NA levels in males and females in ventral tegmental area at subchronic 1 mg/kg.
Altered expression of 172 genes (e.g., downregulated Acsm5, Gpr83; upregulated Fgr, Hes1) in striatum of females at subchronic 1 mg/kg.
Altered expression of 120 genes (e.g., downregulated Vwa5b2, Peli1; upregulated Nbl1, Mdga1) in striatum of females at subchronic 5 mg/kg.
Showed consistent expression changes across doses in seven overlapping genes (Galns, Hps3, Misp3, Nbl1, Samd4a, Slc28a2, Spon2) in striatum of females.
性状 固体
颜色 White to off-white

化学信息

分子量 217.09
分子式 C6H14Cl2N2O2
CAS No. 122323-88-0
别名 Methyl piperazine-2-carboxylate dihydrochloride; METTL3 activator-1

储存&溶解度

储存方式

Store at room temperature, keep dry and cool

In solvent -80°C 1 year
-20°C 6 months
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 250 mg/mL (1151.60 mM; 超声助溶)

DMSO 中的溶解度 : 100 mg/mL (460.64 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO / H2O1 mM4.6064 mL23.0319 mL46.0638 mL115.1596 mL
5 mM0.9213 mL4.6064 mL9.2128 mL23.0319 mL
10 mM0.4606 mL2.3032 mL4.6064 mL11.5160 mL
15 mM0.3071 mL1.5355 mL3.0709 mL7.6773 mL
20 mM0.2303 mL1.1516 mL2.3032 mL5.7580 mL
25 mM0.1843 mL0.9213 mL1.8426 mL4.6064 mL
30 mM0.1535 mL0.7677 mL1.5355 mL3.8387 mL
40 mM0.1152 mL0.5758 mL1.1516 mL2.8790 mL
50 mM0.0921 mL0.4606 mL0.9213 mL2.3032 mL
60 mM0.0768 mL0.3839 mL0.7677 mL1.9193 mL
80 mM0.0576 mL0.2879 mL0.5758 mL1.4395 mL
100 mM0.0461 mL0.2303 mL0.4606 mL1.1516 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础